Clinical Trials Logo

Bypass Complication clinical trials

View clinical trials related to Bypass Complication.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06036017 Recruiting - Delirium Clinical Trials

Care Bundle's Impact on Delirium Prevention in CABG Patients

CareBundle
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This research investigates the effectiveness of a care package used in the care of patients undergoing coronary artery bypass graft (CABG) surgery in preventing postoperative delirium. CABG surgery is a common procedure used to increase blood flow to the heart and is typically applied in patients with severe cardiac diseases. However, this procedure can increase the risk of postoperative delirium, especially among elderly and critically ill patients. In this study, the goal is to reduce this risk by implementing a care package. The care package includes optimal pain management, sleep regulation, mobilization, ensuring patient orientation, and appropriate medication management. The results of the research will be used to determine whether the use of this care package is effective in reducing the risk of delirium after CABG surgery. This could potentially improve patient outcomes and allow for more efficient use of hospital resources.

NCT ID: NCT05542277 Recruiting - Bleeding Clinical Trials

A Pre-market, Multi-center, International, Double-blind, Randomized, Two-arms, Controlled, Prospective Clinical Investigation Assessing the Safety and Performance of a Medical Device (ClearPlasmaâ„¢) for the Treatment of Patients Undergoing Coronary Artery Bypass or Valve Replacement

Start date: November 8, 2022
Phase: N/A
Study type: Interventional

Bleeding is a significant complication in cardiac surgery, with 10-15% of open cardiac surgery patients experiencing major intra- or post-operative bleeding. To address this unmet need, PLAS-FREE LTD has developed ClearPlasmaâ„¢, a single-use, extracorporeal plasma filtration device which extracts plasminogen from plasma to reduce fibrinolysis. The resulting plasminogen-depleted plasma (PDP) is expected to reduce risk of fibrinolysis and bleeding in patients undergoing plasma transfusions.